Kairos Pharma, Ltd.
KAPA
$0.48
-$0.01-2.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 78.64% | 121.36% | 108.78% | 57.59% | 17.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 138.32% | 182.84% | 141.43% | 76.91% | 36.41% |
| Operating Income | -138.32% | -182.84% | -141.43% | -76.91% | -36.41% |
| Income Before Tax | -109.26% | -84.68% | -134.85% | -78.08% | -43.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.26% | -84.68% | -134.85% | -78.08% | -43.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.26% | -84.68% | -134.85% | -78.08% | -43.65% |
| EBIT | -138.32% | -182.84% | -141.43% | -76.91% | -36.41% |
| EBITDA | -148.48% | -198.90% | -154.55% | -84.08% | -40.15% |
| EPS Basic | -32.62% | -18.57% | -73.46% | -43.68% | -29.14% |
| Normalized Basic EPS | -10.49% | -35.95% | -96.82% | -67.14% | -54.80% |
| EPS Diluted | -32.62% | -18.57% | -73.46% | -43.68% | -29.14% |
| Normalized Diluted EPS | -10.49% | -35.95% | -96.82% | -67.14% | -54.80% |
| Average Basic Shares Outstanding | 63.23% | 56.67% | 36.68% | 21.50% | 9.37% |
| Average Diluted Shares Outstanding | 63.23% | 56.67% | 36.68% | 21.50% | 9.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |